| Names | |
|---|---|
| Preferred IUPAC name | Artemether, 4-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylene]-5,6-dihydrobenzo[b][1,4]thiazepin-4-yl]-α,α-dimethylbenzenepropanol |
| Other names | Coartem Riamet Laritem Artefan Duo-Cotecxin Falcimon Amatem Artem-L Cosumart-L |
| Pronunciation | /ˈkɒm.paʊnd ɑːˈtiː.məˌθə ljuː.mefˈæn.trɪn ˈtæb.lət/ |
| Identifiers | |
| CAS Number | 71963-77-4, 82186-77-4 |
| Beilstein Reference | 55930 |
| ChEBI | CHEBI:48533 |
| ChEMBL | CHEMBL2106190 |
| ChemSpider | 22197560 |
| DrugBank | DB06708 |
| ECHA InfoCard | 02aee10e-8767-4a84-8c88-51bed318f84d |
| EC Number | 64067 |
| Gmelin Reference | Gmelin Reference: 83238 |
| KEGG | C07225 |
| MeSH | Dihydroartemisinin-Piperaquine Combination; Artemether; Lumefantrine; Antimalarials; Tablets |
| PubChem CID | 6918520 |
| UNII | 7E77O1278H |
| CompTox Dashboard (EPA) | CompTox Dashboard (EPA) of product Compound Artemether Lumefantrine Tablet: "DTXSID0020854, DTXSID6043424 |
| Properties | |
| Chemical formula | C16H26O5·C30H32Cl3NO |
| Molar mass | 631.53 g/mol |
| Appearance | Yellow oval-shaped tablet |
| Odor | Odorless |
| Solubility in water | Practically insoluble in water |
| log P | 5.2 |
| Basicity (pKb) | 4.98 |
| Dipole moment | 4.52 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 347.7 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | P01BF01 |
| Hazards | |
| Main hazards | May cause hypersensitivity reactions, neurotoxicity, cardiotoxicity (QT prolongation), gastrointestinal disturbances, and hematological effects. |
| GHS labelling | Not classified as hazardous according to GHS |
| Pictograms | Keep out of reach of children, Do not use during pregnancy, Take with food, Store below 30°C, Protect from light, Prescription only |
| Signal word | Warning |
| Precautionary statements | Keep out of reach of children. If swallowed, seek medical advice immediately and show this container or label. Store below 30°C, protect from light and moisture. Do not use after the expiry date. |
| NFPA 704 (fire diamond) | NFPA 704: 1-1-0 |
| LD50 (median dose) | LD50 (oral, rat) for artemether: 895 mg/kg |
| REL (Recommended) | Adult: Artemether 80 mg + Lumefantrine 480 mg per dose, twice daily for 3 days. |
| Related compounds | |
| Related compounds | Artemether Lumefantrine Artemisinin Artemether Injection Artemether Tablets Dihydroartemisinin Artemether-Lumefantrine Oral Suspension Artemether-Lumefantrine Dispersible Tablets Artemotil Artesunate |
| Property | Description |
|---|---|
| Product Name | Compound Artemether Lumefantrine Tablet |
| Main Active Ingredients | Artemether, Lumefantrine |
| IUPAC Name |
Artemether: (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin Lumefantrine: 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol |
| Chemical Formula |
Artemether: C16H26O5 Lumefantrine: C30H32Cl3NO |
| CAS Numbers |
Artemether: 71963-77-4 Lumefantrine: 82186-77-4 |
| Synonyms & Trade Names |
Synonyms and trade names for finished combination products are set by the registration status and region. Artemether is also referred to in pharmacopeia references as methyl ether derivative of artemisinin. Lumefantrine appears in literature as benflumetol. Finished tablets often trade under brand registrations depending on the region and manufacturer. |
| HS Code & Customs Classification |
For compound antimalarial tablets containing Artemether and Lumefantrine, industrial export usually applies HS Code: 3004.90 (Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses or in forms/packings for retail sale, other) Exact classification in customs procedures may rely on latest country-specific customs and regulatory interpretations at the time of export. |
Manufacturing of Artemether Lumefantrine tablets involves sourcing APIs that meet tight impurity and polymorph requirements, as residual manufacturing solvent trace levels and API particle size directly alter tablet bioavailability and final stability. The selection of supplier, batch-to-batch uniformity, and control of polymorphic form require close analytical oversight.
Quality control considers not just assay and dissolution but also practical packaging impact, since lumefantrine absorption sensitivity drives the need for robust humidity barriers and validated secondary containment, depending on end-market environment and regulatory destination. Tablet formulation, binding, and granulation must account for cohesion and segregation risks, as dose uniformity, content mixing and compactibility respond strongly to the supplier-specific properties of incoming APIs.
Key process points are determined by how well wet and dry granulation steps manage moisture and temperature to prevent polymorph changes of artemether, where batch consistency relies on properly controlled environment and validated processing windows. Purification of raw APIs, impurity threshold, and microbial controls depend on certified vendor audit outcomes as well as internal audit and readiness criteria.
Finished batch release hinges on in-process and final analysis sampling that captures content uniformity, impurity profile, and dissolution across representative dosage forms, and release criteria are always harmonized with prevailing pharmacopoeial standards for regulated export markets.
Compound Artemether Lumefantrine Tablets are typically prepared as compressed, uncoated or film-coated solid tablets. Color varies by formulation, usually yellow to orange, reflecting the pigmentation of lumefantrine. Odorlessness characterizes finished tablets, with only faint traces noticed from excipients if broken. Melting points are not defined for the composite tablet, as both artemether and lumefantrine exist as dispersed actives within an excipient matrix. Neither component volatilizes under ambient conditions. Both pure artemether and lumefantrine are lipophilic, non-hygroscopic powders with melting points above ambient temperature. Tablet density and hardness fall within process-dependent ranges, set per batch by compaction force and excipient fraction.
In industrial storage, batches are susceptible to hydrolysis of artemether at elevated humidity, and oxidative degradation of both actives if exposed to air, light, or elevated temperatures. Tablets are sensitive to photodegradation, most notably for lumefantrine. Stability strongly depends on excipient selection and protective packaging. Notable batch variability in long-term stability arises if protective excipients or film coatings are omitted or improperly applied.
Both artemether and lumefantrine are poorly soluble in water but dissolve in certain organic solvents. This low aqueous solubility drives formulation challenges, influencing tablet dissolution rates and bioavailability. Solution preparations for assay or impurity testing rely on suitable organic phases, often recommended by local pharmacopoeia standards.
Specifications depend on the intended market (e.g., hospital, retail, export) and are closely tied to regional pharmacopeial standards. Content uniformity, disintegration time, hardness, friability, and color parameters are batch-defined. Each specification is finalized through joint review with customers and regulatory authorities, reflecting end-use demands.
Impurity levels stem from both starting material and process steps. In-house monitoring focuses on related substances: artemisinin-derived byproducts, process residuals, and degradation products. Monitoring targets both total and specific impurities recommended by the most stringent regulatory monographs. Impurity limits are not universal; final acceptance criteria reference customer specifications, bilateral agreements, and product grade requirements.
Testing protocols follow local and international pharmacopoeial monographs (such as USP, EP, or ChP) according to shipment destination. Assay methods typically use HPLC or equivalent validated procedures for both artemether and lumefantrine content, with supporting tests for dissolution, disintegration, and mechanical properties. Reference standards and control samples are batch-specific and documented in the batch record.
Raw material selection, especially for artemether and lumefantrine, relies on certified sources with traceable origin and validated purity. Artemether is sourced from artemisinin-extracting manufacturers with audit-compliant facilities. Lumefantrine procurement follows similar scrutiny, with attention to impurity profile consistency.
The manufacturer does not synthesize actives in-house for tablet manufacturing; synthesis of artemether typically involves reduction and etherification of artemisinin, while lumefantrine results from condensation of a fluorene derivative. Knowledge of supplier production routes guides selection to mitigate process-based impurity carryover.
Manufacturing begins with precise weighing, sieving, and blending of actives and excipients. Critical control points include moisture management, blending uniformity, and compaction pressure control. Purification concerns focus on active pharmaceutical ingredients (APIs) received, with in-process controls for contamination and degradation prevention. Tablet coating (when applied) provides additional protection against oxidation and photolysis, necessitating consistent application thickness and thorough drying.
Every batch undergoes in-process sampling for weight, content, and impurity checks. Batch release protocols require passing all critical specifications established with stakeholders. Sampling plans and release criteria are tailored to the batch scale and customer requirements.
Artemether and lumefantrine are chemically stable during tableting, but both undergo hydrolysis and oxidative breakdown outside tolerance ranges for humidity and light. Derivatization is not part of the manufacturing process for tablet forms, although both actives have the potential for chemical modification in research or intermediate synthesis stages.
Active pharmaceutical ingredient synthesis involves specialized conditions, but direct chemical reaction does not occur during tablet formation. The blending and compression are strictly physical processes, typically performed at ambient temperature and controlled humidity to minimize degradation rates.
Manufacturing focuses on the fixed-dose tablet. Alternate dosage forms and combination therapies are feasible by adjusting formulation and process steps; any such modification requires new setpoints for process and impurity control points as well as updated regulatory filings. Tablets are designed as finished-dose forms without intermediates or in situ derivative formation.
Optimal storage specifies low humidity, moderate temperatures, and protection from direct light exposure. Controlled storage with desiccants and non-reactive, light-opaque containers is essential for bulk and packed tablets. Atmospheric protection is typically achieved with sealed aluminum blisters or high-barrier bottles.
Container systems are selected for inertness towards tablets—plastic or glass bottles and aluminum blisters prevent interaction or leaching. Any deviation in packaging selection must undergo extractable and leachable studies before approval for use with this product.
Shelf life depends on packaging, temperature, and humidity control, with degradation observed as color change, loss of content, or tablet friability exceeding release criteria. Shelf life is batch- and packaging-specific, set according to real-time and accelerated stability studies. Any sign of chipping, discoloration, or odor in stored tablets requires investigation and follow-up with the supplier chain.
Compound Artemether Lumefantrine Tablets carry health hazard designations based on API content and intended use, with precautions to avoid ingestion or exposure outside of therapeutic guidance. Bulk handling in manufacturing mandates hazard labelling and staff training under prevailing chemical safety regulations.
Operator safety in production requires proper PPE, dust control, and safe handling techniques to avoid accidental ingestion or inhalation of powders. Precautionary guidelines reflect the risk from both active and inert components, requiring immediate response protocols in case of accidental contact or exposure.
Exposure limits reflect the toxicity of artemether and lumefantrine as pharmacological actives, applied with strict compartmentalization in manufacturing to prevent cross-contamination. Handling instructions for technicians include use of gloves, masks, and controlled areas. All spills or contamination incidents undergo prompt clean-up and documentation. Occupational exposure reviews align with the latest health and safety practices and updated regulatory requirements.
Market demand for Artemether Lumefantrine Tablets hinges on both WHO-prequalified and locally registered product supply flows. Annual capacity fluctuates with campaign projects, public health tenders, and regional NGO procurement schedules. Actual capacity output responds closely to active ingredient sourcing, API batch release rates, and intermediate stock turnover. Scale-up for global tenders requires longer planning compared to local or emergency lots. Key practical bottlenecks arise from Artemisinin derivative extraction and controlled synthesis batch yields. Unplanned regulatory changes or API force majeures can impact real-time batch availability, so rolling forecast adjustment and safety stock management underpin consistent supply for larger forward contracts.
Average lead times range from twelve to eighteen weeks for standard orders, largely influenced by raw material lot release cycles and packaging lead synchronization. MOQ follows batch scale practices, frequently dictated by blister or bottle fill efficiency. Lower-volume custom orders face longer queue times and higher per-unit costs due to line changeover and residual validation needs.
Blister strips and bottle packs dominate coating and secondary packaging formats. Both options serve compliance-driven national standard requirements and NGO distribution preferences. Modifications such as child-resistant blisters or serialized packaging can be implemented on client request, typically affecting both tooling schedule and validation protocol. Bulk packs for regional distributors are available by negotiation, subject to transport stability and regulatory agreements.
Standard export practices support FCA, FOB, or CIF major ports. Specialized temperature and humidity control during ocean or air transport aligns with product stability data. Payment terms often settle on LC at sight for new partners; D/P or T/T terms apply for repeat or long-term supply agreements. Credit term flexibility corresponds to order history, procurement entity, and market risk profile.
Active ingredient costs make up a dominant portion of the finished tablet pricing. Artemether, derived from Artemisinin, faces historic volatility due to agriculture yield cycles, extraction efficiency, and geopolitical influences in major production regions. Lumefantrine costing is steadier but subject to upstream intermediate price movements, especially with global API supply chain constraints or regulatory interventions. Excipients, packaging films, and regulatory batch costs form smaller but non-trivial components, especially in smaller lot or specialty packaging.
Key drivers of cost swings stem from three principal sources: Artemisinin crop output variability, plant extraction cost shifts due to labor or solvent market changes, and the regulatory-driven access to high-purity intermediates. Sudden policy moves, export limitations, or crop disease events have decisive impact on annual input cost averages. Synthetic route development could stabilize Artemether input costs, but no universal solution currently matches botanical supply scale.
Grade, purity, and lot certification level result in notable price stratification. WHO prequalified tablets carry added cost for quality assurance, global regulatory testing, and serialization. National-level registration packs fall into mid-tier cost bands, primarily due to country-specific release protocols. Bulk grades with less rigorous certification typically only see distribution inside national borders or via private-sector channels. Packaging format and shipment mode also affect lot pricing, with full secondary pack lines costing more than plain bulk pack shipments.
The dominant market drivers remain large-scale malaria programs funded by entities such as the Global Fund, UNICEF, and regional governments. Sub-Saharan Africa absorbs the majority of global volume, with intermittent demand spikes based on campaign cycles. Market entry for alternative therapies or generic formulations influences pricing pressure more than organic demand change.
The US and EU import smaller, highly regulated volumes for travel medicine or research, requiring top-tier certification and strict serialization. Japan sources infrequently, typically limited to humanitarian or emergency supply. India and China are central both in manufacturing API and supplying finished dose forms, serving both local and global procurement. Indian manufacturers frequently operate under aggressive cost models, leveraging scale and local raw material access, while Chinese plants control much of the Artemisinin extraction supply chain.
Industry forecasts for 2026 suggest moderate price stabilization if recent expansion in Artemisinin cultivation persists and synthetic intermediate pathways become commercially viable on a wider scale. Price downward pressure remains likely if more Asian manufacturers secure WHO prequalification, but any significant policy change or supply shock in the primary extraction regions could reverse these trends. Data are derived from tender records, API market report tracking, and public procurement disclosures. Rolling analysis combines harvest cycle forecasts, regulatory market access, and input cost trendlines.
Artemisinin market expansion and parallel development of synthetic routes have recently featured in industry news, with global agencies pushing for greater supply resilience. New variants and resistance trends in malaria-endemic areas push demand for standardized, quality-assured combination therapies.
WHO PQ and various emerging market regulators have updated dossier requirements around impurity profiling and serialization, raising both compliance costs and the technical barrier for new entry. Frequent update cycles now require manufacturers to devote increased resources to ongoing stability studies and adaptive dossier management.
Manufacturers adjust production schedules to buffer against peak season volatility, increase upstream raw material audits, and build out modular packaging capabilities to meet evolving destination market requirements. For compliance, new analytical equipment and continuous training programs ensure alignment with the evolving regulatory landscape. Strategic alliances with extraction processors and raw material cooperatives provide early warning for crop or supply chain disruption risks, helping to secure delivery commitments even in volatile conditions.
Compound Artemether Lumefantrine Tablet serves in human pharmaceutical manufacturing, primarily for anti-malarial finished dosage forms. The product pool supports both branded and generic pharmaceutical companies, along with specialized contract manufacturers. Bulk supply is directed towards markets operating under stringent regulatory frameworks, such as WHO prequalification, as well as regions with national pharmacopeial standards.
Usage of this combination tablet spans first-line malaria therapy, emergency anti-malarial kits, and global health procurement programs. In our manufacturing experience, large tenders from global health agencies typically follow multinational regulatory pathways, while regional procurement may request national-standard conformity.
| Grade | Key Application Segments | Remarks |
|---|---|---|
| Pharmaceutical Regulatory Grade | Formulation for international donor projects, high-compliance generics, public health procurement | Complies with specifications required by stringent authorities. Batch history and regulatory documentation package provided. Targeted for markets with heightened oversight and traceability rules. |
| National/Local Market Grade | Local contract manufacturing, domestic generics, commercial pharmacies | Manufactured according to local/national pharmacopeia or client specifications. Regulatory filing package aligned to the respective country standard. Assay and impurity profiles may reflect local compliance cut-offs. |
| Process Development & R&D Grade | Pre-formulation work, process optimization, non-commercial research use | Intended for laboratory evaluation, formulation trials, or non-cGMP downstream processing. This grade serves teams focusing on process adaptation or compatibility studies rather than immediate commercial batch release. |
All grades share the core active pharmaceutical ingredients—Artemether and Lumefantrine—with defined stoichiometry and polymorphic forms controlled by the synthetic route and crystallization process.
The above criteria tune based on source route and specific customer request, especially for novel formulation work, regulatory pathway, or complex market requirements.
Clarity on the end-use environment surfaces the primary grade direction. Production for tender-style contracts backed by public health agencies demands regulatory-grade output, whereas domestic generics may accept national-grade criteria. Projects in pharmaceutical development or pilot formulation will often benefit most from dedicated R&D grade.
Review the destination country’s market application pathway and referenced pharmacopeia. Multinational approval channels (e.g., WHO PQ, US FDA) shape batch documentation, impurity limits, and drug master file support. In-house regulatory leads should coordinate our technical and quality team for dossier alignment where region-specific regulatory frameworks diverge.
Some applications call for tighter control of process-related impurities, off-target isomers, or specific solvent residues. Where higher sensitivity matters—such as innovative pediatric formulations—discuss customized impurity profiling. For national standard pharma grades, quality group adapts batch release specs in dialogue with the formulators and market access teams to reflect current legal expectations.
Procurement projections drive batch size, which in turn influences the process route, campaign planning, and costs. Regulatory grades often command higher manufacturing overhead per lot, stemming from extra quality assurance and compliance documentation. National/R&D batches may follow flexible scheduling, supporting agile project timelines or cost minimization.
Obtain a representative sample from the chosen grade. Our QC lab issues a technical validation pack, including chromatographic profiles, assay results, and stability snapshots. Customer-side technical teams often run blending, compression, dissolution, and stability trials before moving to full-lot procurement. Feedback from these exercises closes the loop, enabling production to tune upcoming campaigns to address observed processing challenges or formulation gaps.
Direct oversight from our integrated technical, QA, and production teams ensures that every batch of Compound Artemether Lumefantrine Tablet receives full evaluation under an established quality system. QA managers implement site-wide protocols aligned with internationally recognized quality management systems. Certification audits focus on the traceability of each produced lot, process consistency, and continual improvement. Individual production areas for artemether and lumefantrine operate under documented SOPs that have undergone external review as required by regulatory markets accepting product from our region.
We recognize that regulatory expectations differ by export destination. Production lots for customers requiring stringent oversight—such as public health procurement or institutional tenders—are released only when the internal QMS demonstrates system-wide control as evidenced by management reviews, critical deviation tracking, and successful completion of annual third-party recertification.
The full process chain from raw material procurement to finished tablet is supported with documentation for process validation, cleaning validation, and analytical method verification suitable for pharmaceutical finished dosage forms. For artemether lumefantrine combination tablets, independence of API batch origin, process flow, and core critical control points—such as blending, granulation, and compression—form part of the product file for regulatory submissions.
Batch certificates of analysis (COA) are routinely issued for each finished lot, and shipments intended for regulated markets are supported by complete product documentation packs aligned with current pharmacopeial standards, submitting to customer or authority audit and inspection as required. Typical certification documents may include: GMP certificates from qualified auditors, process validation summaries, microbial and physical control reports, and compliance statements against customer tender specifications.
A full document trail is created for every manufactured lot. Raw material traceability, manufacturing records, batch production logs, control testing protocols, cleaning schedules, and analytical reports all form part of our internal record-keeping system. Document requests cover process descriptions, change control history, deviation reports, certificate archives, and validation summaries. Upon customer request, sample retention documentation, method transfer protocols, and additional third-party certificates can be provided. Process upgrades or significant equipment changes trigger revision of batch records and process descriptions to maintain maximum traceability.
Core API sourcing has been secured through direct sourcing agreements and close supplier qualification programs. Facility capacity planning utilizes rolling forecast models based on downstream public-sector procurement cycles. Production scheduling weighs customer priority orders, seasonality effects on raw material supply, and long-term off-take agreements to smooth supply bottlenecks. Adaptable cooperation modules allow contract manufacturing for customers demanding dedicated lines or special labeling. For clients needing year-round steady volumes, rolling release contracts anchor minimum supply while allowing volume adjustment to fit market dynamics.
Core production outputs are mapped to both domestic and international order flows, accounting for batch-specific processing times, analytical loads, and QA batch release. Flexibility in API isolation and tablet line operation enables surge runs for time-sensitive procurement campaigns, such as government or NGO malaria interventions. Site management focuses on minimizing downtime, rapid change-over between product variations, and inventory management for key intermediates. Customers requiring documentation on volume security or production plans receive periodic supply chain risk assessment and inventory summary reports.
Sample application for technical evaluation or customer pilot studies follows a formal internal workflow. Requests are assigned a registration number to ensure full traceability from dispatch through subsequent production batch. Standard sample package sizes, accompanied by batch-specific COA, are shipped from the production lot most representative of routine commercial scale. Clients may specify particular process attributes or analytical requirements for sample lots. Technical support provides additional clarification on sample preparation, recommended use protocols, and handling conditions as needed.
Flexibility in cooperation supports procurement scenarios including framework agreements, spot purchase, dedicated production slots, and custom formulation development. For customers operating in fluctuation-prone environments, cooperation terms include rolling volume commitments, split-lot deliveries, and alternate shipping point arrangements. Where customer forecasts are uncertain, cooperative planning workshops establish decision points for scaling up or down based on mutual assessment of market signals, stock levels, and supply risk. Collaboration on regulatory submissions, dossier sharing under appropriate confidentiality safeguards, and joint development on product upgrades support long-term supply partnerships as required by public or private tenders.
Research in compound artemether lumefantrine tablets remains driven by the global challenge of antimalarial drug resistance and the demand for reliable oral therapies in endemic regions. Key effort goes into optimizing the ratio of artemether to lumefantrine for pharmacokinetic benefit, improving pediatric formulations, and reducing dosing frequency without sacrificing therapeutic outcomes. Manufacturers observe continual pressure to deliver formulations that maintain consistent bioavailability despite variations in excipient grades and local raw material profiles.
Expansion into combination therapies for broader spectrum protozoal diseases and co-administration with antipyretics or adjunctive agents shapes current research focus. Formulation compatibility studies guide decisions around multi-drug co-formulation, with research attention on maintaining stability over complicated storage and distribution environments, especially for public health tenders in tropical climates.
Lumefantrine’s low solubility remains a core manufacturing challenge, particularly in securing content uniformity and dissolution consistency in large-scale tablet production. Process refinements, such as wet granulation optimization or adoption of newer solubilizers, have delivered measurable reductions in batch-to-batch variability for higher grade outputs. Contaminant control, particularly in solvent use and cross-contamination risk with other APIs, shapes in-process control logic. Recent breakthroughs in solvent recovery and closed-system granulation have improved workplace safety and reduced environmental emissions.
Demand for compound artemether lumefantrine tablets follows trends in international procurement, driven largely by government, NGO, and health agency tenders. Over a three to five year horizon, volatility in malaria incidence, donor policy, and regulatory harmonization impact short-term purchasing cycles. Manufacturers that align with evolving pharmacopeial monographs and maintain registration flexibility across high-burden regions see steadier demand.
The transition toward continuous manufacturing and integration of process analytical technology supports more robust process control and faster scale-up. Machine vision-driven tablet inspection and gravimetric feeder control now play a greater role in maintaining dosing consistency, particularly where local regulations require in-process sampling and real-time release testing.
Environmental aspects in production focus on minimizing solvent consumption in lumefantrine processing, alongside energy optimization in drying steps. New catalytic strategies for artemether synthesis and closed-cycle solvent recycling receive priority in investment planning. Finished product packaging increasingly adopts recyclable materials, which introduces new compatibility testing against tropical storage conditions.
Support covers technical validation for new product registrations, assistance with stability trial design, and guidance on local compliance hurdles. Product-specific technical consultation addresses application in co-blistered regimens, formulation troubleshooting for local excipient sources, and process validation support based on customer’s line capability.
Manufacturing technical teams provide on-site or remote assistance for tableting process optimization, focusing on feeder calibration, granulation end-point identification, and humidity control, as these factors directly affect dissolution and stability outcomes. Guidance for downstream process integration, such as coating compatibility and blister-packing performance, adapts to client machinery and local environmental constraints.
Commitment covers timely documentation for regulatory submission, root-cause analysis on observed deviations, and batch traceability support per client specification. Quality control feedback loops enable rapid response to adverse trend signals, with corrective action and preventive action (CAPA) procedures matched to technical findings. Replacement supply and technical action plans pivot on batch record review, rather than generic warranty language.
Our facility specializes in the direct synthesis and tableting of Compound Artemether Lumefantrine. Each production batch follows validated processes from raw material selection through to final tableting. We carry out all synthesis, blending, tablet pressing, and coating on-site, maintaining oversight at every stage. The plant employs automated systems to regulate environmental controls, particle size, and blend consistency, minimizing lot-to-lot variation.
Pharmaceutical manufacturers use our Compound Artemether Lumefantrine Tablet as a primary component in finished anti-malarial dosage forms. Our product serves formulators and brands producing generic and branded malaria treatments for distribution in public health tenders, hospital supply chains, and high-burden malaria regions. Our tablets fit well into automated secondary packaging or repackaging operations for institutional suppliers.
Quality control functions as a core part of our operation. We run HPLC assay, dissolution, and impurity profiling on every batch. Reference standards come from certified global sources, and we independently verify both the artemether and lumefantrine fractions throughout production. Our stability program tracks shelf-life in real temperature and humidity conditions before release for commerce.
Packaging lines support multiple regional and commercial formats. Options include alu-alu blister, foil strip, and bulk bottle configurations, all processed under GMP environments. We have experience shipping tablets under cold chain and standard conditions, providing full traceability with serialized batch labeling and tamper-proof secondary cartons. Integrated logistics partners support distribution both to international ports and directly to contract packagers.
Formulation and regulatory specialists on our team help industrial buyers navigate registration and market entry requirements. Consultation covers tablet validation, stability data support, and compliance with pharmacopoeial monographs. When clients adopt new packaging or require dose adaptation, our experts advise on in-plant handling and process compatibility, helping reduce the time to commercial readiness.
Procurement teams and operations managers benefit from the transparency and control inherent in our vertically integrated production. For distributors supplying government programs, health agencies, or large-scale tenders, our broad experience in documentation, regulatory compliance, and stable supply offers practical risk reduction. Manufacturers find value in reliable order fulfillment, technical backup, and flexibility to meet project-specific volume or presentation requirements without compromising delivery timelines.
| Aspect | Key Points |
|---|---|
| Production | Full in-house control from synthesis to final blistering |
| Quality Assurance | Analytical testing on every lot; stability data monitored in-house |
| Packaging | Customizable formats; meets global transport requirements |
| Technical Support | Direct access to process, formulation, and compliance expertise |
| Supply Capability | Established capacity for high-volume, deadline-driven tenders |
As the direct manufacturer of compound Artemether Lumefantrine tablets, we address questions around storage and shelf life based on our production expertise, in-house stability data, and industry practice. Maintaining the stability and reliable therapeutic value of this antimalarial combination relies on controlling both the physical and chemical integrity of the tablets from our facility through end use.
The two active ingredients—artemether and lumefantrine—are both vulnerable to heat, moisture, and high humidity. Degradation of either active limits the biological outcome and can directly impact treatment success. For this reason, current Good Manufacturing Practice (cGMP) process at our facility involves a stringent drying, coating, and packaging stage. The finished tablets are packaged into high-barrier blisters or HDPE bottles fitted with desiccants as a standard. These components minimize exposure to water vapor and oxygen, limiting risk of hydrolysis, photodegradation, or oxidation during storage and transport.
We recommend storing these tablets in a dry, well-ventilated area away from direct sunlight and heat. Storage at temperatures below 30°C is critical. Our own data, collected from ongoing stability studies following International Council for Harmonisation guidance, shows that prolonged temperatures above 30°C speed up artemether breakdown and can affect the disintegration profile of the finished tablet. Avoiding freeze-thaw cycles also prevents potential changes in the physical profile, as freeze-thaw conditions can induce microcracking of the film coating and alter dissolution.
Excessive moisture in the storage area has led to tablet softening and sticking in stress-test samples. We have seen that even short exposure to high humidity can degrade artemether and cause clumping that hampers accurate dosing. Tight closure of primary packaging and keeping tablets in the original blister or bottle until the point of administration offers reliable protection. We instruct our downstream stakeholders to store and distribute within these guidelines, which are based on both our internal validation and common pharmaceutical standards.
Our most recent full-scale stability batches confirm a shelf life of up to two years when stored below 30°C in the original unopened packaging. This timeline depends on adherence to recommended storage. Under these conditions, both actives hold acceptable potency, and no significant impurities accumulate. Regular sampling from retained market batches and controlled storage facilities lets us confirm continuing compliance with regulatory standards.
Once a blister is opened or a bottle is unsealed, we recommend using the tablets within a short period for best therapeutic effect. Where high ambient temperatures are unavoidable, insulated transport and storage are necessary. We offer technical advice to large-scale buyers looking to optimize conditions across remote or high-risk environments.
Any uncertainty about temperature excursions or accidental exposure to moisture should prompt a review by a technical team using visual checks and validated laboratory methods. We carry out such analysis for our export clients to ensure continued confidence in our product’s performance.
In practice, most stability failures trace back to improper handling outside the original packaging or uncontrolled high-temperature storage. Our technical representatives provide ongoing support to downstream partners and end-users, focusing on real-world solutions for field conditions. Where necessary, we can supply detailed protocols for temperature control, data loggers, and monitoring devices to help clients comply with quality standards throughout the product’s lifecycle.
Our direct manufacturing oversight ensures customers receive clear, actionable guidelines to protect the therapeutic power of Artemether Lumefantrine tablets, underscoring our long-term focus on product reliability for all end markets.
Our factory continues to prioritize stable supply and responsible production of Compound Artemether Lumefantrine Tablets to support global malaria control programs and reliable procurement for pharmaceutical partners. Questions about minimum order quantity, current readiness and actual delivery schedules have grown more frequent as organizations work through changes in demand, logistical uncertainties, and shifting regulatory timelines across regions.
Our batch manufacturing line for these fixed-dose combination tablets runs most efficiently at minimum lot sizes tailored to both GMP compliance and safe handling regulations. From our direct experience, the minimum order quantity often starts from 100,000 tablets per strength and packaging configuration. This threshold ensures consistent quality control and traceable documentation per run – critical for an antimalarial API product distributed internationally and subject to stringent government review. Smaller orders risk cross-batch contamination, raise per unit cost, and create supply pressure that is difficult to absorb on the production line. When medical programs forecast high-volume campaigns or replenish stockpiles, larger planned quantities strengthen both economies of scale and certainty in long-term delivery.
Our typical lead time for Compound Artemether Lumefantrine Tablets falls within 4–8 weeks ex works, following formal order confirmation and finalized artwork requirements. This period covers raw materials sourcing, tablet compression, packaging, in-house QC release, and external batch certification where required by health authorities. During periods of elevated demand or unexpected spikes—often tied to seasonal outbreaks or new tenders—we may allocate limited inventory from strategic finished goods warehouses. As of our latest production cycle, we have reserved capacity for health authority-approved shipments but do not hold continuous open stock for spot purchase as a routine practice. Most of our customers align ordering schedules with annual procurement plans or rolling multi-month agreements, and our technical team facilitates firm lead times based on forward planning.
In contrast to some generic oral medications that lend themselves to mass batch production with open stock holding, the shelf life and stability profile of artemisinin-based combinations call for careful planning from raw material intake to finished product dispatch. We coordinate closely with active pharmaceutical ingredient suppliers for both Artemether and Lumefantrine, since disruptions upstream can affect our batch release sequence. Our technical and procurement teams rely on robust vendor audits and strong working relationships with key input producers; any change in the global API supply landscape is immediately reflected in our delivery promises.
Direct manufacturers assume full responsibility to guide buyers through technical documentation, bioequivalence reference, emergency shipment requests, and post-market technical support. We maintain a dedicated regulatory affairs group for dossier updates, and our documentation package can be extended to meet local registration or tender requirements. All specification sheets, batch analysis, and CoAs originate directly from our in-house quality lab, and we issue export paperwork straight from the facility—avoiding ambiguity or relabeling often introduced by third-party trading routes.
Buyers working with our technical sales team engage with the actual plant floor operations, get transparent production scheduling, and can request customization to fit packaging and molecule ratios meeting field program guidelines. We welcome inquiries for tailored delivery plans as health sector priorities evolve and regional stockpiles change.
Our company manufactures Artemether Lumefantrine Tablets using strict standards designed to align with both the World Health Organization (WHO) prequalification requirements and major local health authorities' expectations. There is no room for error in the fight against malaria. From the processing of raw materials to the final tablet, every stage meets globally recognized guidelines, integrating comprehensive in-process quality control and validation.
WHO prequalification serves as an important international reference, particularly in markets relying on donor-funded procurement schemes. Many importers, government tenders, and NGOs look for this mark as assurance of quality, safety, and batch consistency. Our compliance process includes stability studies in real climatic conditions, bioequivalence evaluation, and Good Manufacturing Practice (GMP) documentation from recognized authorities. These steps are not limited to checks for documentation; experienced auditors examine process integrity and traceability down to the excipient level.
Every country sets detailed guidelines for import and distribution of antimalarial medicines. Our registration dossiers always stick close to those markets’ specific pharmacopoeial monographs, packaging rules, labeling in local languages where applicable, and traceability requirements for serialization. Our technical dossier spans active and inactive ingredient specifications, manufacturing process description, certificates of analysis, analytical validation reports, and clinical evidence to support product claims.
No shipment leaves our logistics centers without the entire suite of valid documents. These typically include the Certificate of Pharmaceutical Product (CPP) under the WHO format if requested, GMP certificates from a stringent authority, and a full Certificate of Analysis specific to the shipped batch. We provide the importer's agent with a technical data package, product labeling information, sample packaging, and information leaflets as required by the destination’s regulatory agency.
As the direct manufacturer, concerns about documentation for clearance and distribution are often brought up by our partners. Over the years, we’ve invested in electronic batch tracking, secure serialization on packaging, and staff training on regulatory audit procedures. Our regulatory affairs team possesses hands-on experience in dossier submission, responding efficiently to questions from major agencies and rapidly securing agency approvals when asked for additional data.
Some markets still present unpredictable regulatory hurdles, sometimes in local dossier formats or requiring supplementary testing on arrival. We handle such scenarios by working closely with in-market labs and ministries, ensuring our product consistently passes these checks. The underlying challenge in many instances is changes or lack of clarity in national regulations. Our technical documentation adapts with frequent regulatory updates, emphasizing rapid response and proactive planning rather than retroactive troubleshooting.
Our organization has built its reputation on strict adherence to both international and local standards. Every shipment of Artemether Lumefantrine Tablets carries our assurance of compliance, direct traceability to our factory batch records, and all documentation necessary for lawful importation and market release. Our production and quality assurance teams actively monitor global regulatory developments to guarantee uninterrupted supply and full compliance at every step.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
